Patent FR1181707A successfully refreshed from Google Patents.
US4460561A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
Assignee: Individual
•
Filing: 1982-09-08
•
Granted: 1984-07-17
•
Expires: 2002-09-08
Abstract
Abstract Methods are provided for using radiolabeled antibodies specific to intracellular tumor-associated markers for detection, localization and therapy of tumors. Injectable compositions for use in the methods of the invention are also provided.
Inventors
- 👤 M. David Goldenberg
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 16:18
CPC Classifications
A; A61; A61K; A61K51/00; A61K51/02; A61K51/04; A61K51/08; A61K51/10; A61K51/1045; A61K51/1048; C; C07; C07K; C07K16/00; C07K16/18; C07K16/28; C07K16/30; C07K16/3007; A61K2121/00; A61K2123/00; A61K38/00
Claims Analysis
Total Claims: 20
Claim 1
Independent Claim
197 words
A method for detecting and localizing a tumor which either produces or is associated with an intracellular marker substance, which comprises injecting a human subject parenterally with an antibody specific to said marker substance and radiolabeled with a pharmacologically inert radioisotope capable of detection using a photoscanning device, and with indifferent immunoglobulin from the same or different species as that used to prepare said specific antibody, said indifferent immunoglobulin being radiolabeled with a pharmacologically inert radioisotope of a different element from that used to label the specific antibody and emitting at an energy capable of independent detection using said photoscanning device, the radiolabeling be so effected that the kinetics and distribution of the radiolabeled specific antibody and indifferent immunoglobulin in said subject are substantially the same during the time period required for scanning; and scanning the subject with said photoscanning device, the level of activity of the labeled indifferent immunoglobulin being used to determine the distribution of background activity due to non-targeted specific antibody, said background activity being subtracted from the total activity of specific antibody, whereby the activity of substantially only the targeted tumor-localized specific antibody is determined and said tumor is thereby detected and localized.
Claim 2
Independent Claim
197 words
A method for detecting and localizing a tumor which either produces or is associated with an intracellular marker substance, which comprises injecting a human subject parenterally with an antibody specific to said marker substance and radiolabeled with a pharmacologically inert radioisotope capable of detection using a photoscanning device, and with indifferent immunoglobulin from the same or different species as that used to prepare said specific antibody, said indifferent immunoglobulin being radiolabeled with a pharmacologically inert radioisotope of a different element from that used to label the specific antibody and emitting at an energy capable of independent detection using said photoscanning device, the radiolabeling be so effected that the kinetics and distribution of the radiolabeled specific antibody and indifferent immunoglobulin in said subject are substantially the same during the time period required for scanning; and scanning the subject with said photoscanning device, the level of activity of the labeled indifferent immunoglobulin being used to determine the distribution of background activity due to non-targeted specific antibody, said background activity being subtracted from the total activity of specific antibody, whereby the activity of substantially only the targeted tumor-localized specific antibody is determined and said tumor is thereby detected and localized.
Claim 3
Dependent Claim
51 words
The method of claim 1, wherein the specific antibody is radiolabeled with one of, and the indifferent immunoglobulin is labeled with another of Iodine-131, Iodine-123, Iodine-126, Iodine-133, Bromine-77, Indium-111, Indium-113m, Gallium-67, Gallium-68, Ruthenium-95, Ruthenium-97, Ruthenium-103, Ruthenium-105, Mercury-197, Mercury-203, Rhenium-99m, Rhenium-105, Rhenium-101, Scandium-47, Tellurium-121m, Tellurium-122m, Tellurium-125m, Thulium-165, Thulium-167, Thulium-168, Technetium-99m or Fluorine-18.
Claim 4
Dependent Claim
33 words
The method of claim 1, wherein the specific antibody is radiolabeled with one of I-131, Ga-67, Tc-99m or In-111 and the indifferent immunoglobulin is radiolabeled with another of I-131, Ga-67, Tc-99m or In-111.
Claim 5
Dependent Claim
19 words
The method of claim 1, wherein tumor localization is effected within 48 hours of injection of the labeled immunoglobulins.
Claim 6
Dependent Claim
14 words
The method of claim 4, wherein localization is effected within 24 hours of injection.
Claim 7
Dependent Claim
26 words
The method of claim 1, wherein the specific antibody is specific to human chorionic gonadotropin (HCG) or its beta-subunit, alpha fetoprotein (AFP) or colon-specific antigen-p (CSAp).
Claim 8
Independent Claim
247 words
A method of tumor radiotherapy, which comprises parenterally injecting into a human subject having a tumor which produces or is associated with an intracellular marker substance a radiotherapeutically effective amount of an antibody which is specific to said marker substance and radiolabeled with a pharmacologically inert radioisotope capable of detection with a photoscanning device, said labeled antibody further containing in chemical combination at least one addend containing at least five atoms of boron with at least a natural abundance of Boron-10 isotope; injecting into said subject indifferent immunoglobulin from the same or different species as that used to prepare said specific antibody, said indifferent immunoglobulin being radiolabeled with a pharmacologically inert radioisotope of a different element from that used to label the specific antibody and emitting at an energy capable of independent detection using said photoscanning device, the radiolabeling being so effected that the kinetics and distribution of the radiolabeled specific antibody and indifferent immunoglobulin in said subject are substantially the same during the time period required for scanning; localizing the tumor by scanning the subject with said photoscanning device, the level of activity of the labeled indifferent immunoglobulin being used to determine the distribution of background activity due to non-targeted specific antibody, said background activity being subtracted from the total activity of specific antibody, whereby the activity of substantially only the targeted tumor-localized specific antibody is determined and said tumor is thereby detected and localized; and directing a beam of thermal neutrons at said tumor location.
Claim 9
Independent Claim
247 words
A method of tumor radiotherapy, which comprises parenterally injecting into a human subject having a tumor which produces or is associated with an intracellular marker substance a radiotherapeutically effective amount of an antibody which is specific to said marker substance and radiolabeled with a pharmacologically inert radioisotope capable of detection with a photoscanning device, said labeled antibody further containing in chemical combination at least one addend containing at least five atoms of boron with at least a natural abundance of Boron-10 isotope; injecting into said subject indifferent immunoglobulin from the same or different species as that used to prepare said specific antibody, said indifferent immunoglobulin being radiolabeled with a pharmacologically inert radioisotope of a different element from that used to label the specific antibody and emitting at an energy capable of independent detection using said photoscanning device, the radiolabeling being so effected that the kinetics and distribution of the radiolabeled specific antibody and indifferent immunoglobulin in said subject are substantially the same during the time period required for scanning; localizing the tumor by scanning the subject with said photoscanning device, the level of activity of the labeled indifferent immunoglobulin being used to determine the distribution of background activity due to non-targeted specific antibody, said background activity being subtracted from the total activity of specific antibody, whereby the activity of substantially only the targeted tumor-localized specific antibody is determined and said tumor is thereby detected and localized; and directing a beam of thermal neutrons at said tumor location.
Claim 10
Dependent Claim
26 words
The method of claim 7, wherein the specific antibody is specific to human chorionic gonadotropin (HCG) or its beta-subunit, alpha fetoprotein (AFP) or colon-specific antigen-p (CSAp).
Claim 11
Dependent Claim
137 words
An injectable composition, which comprises (a) a substantially monospecific antibody having a specific immunoreactivity of at least 70% to an intracellular marker substance produced by or associated with a tumor and a cross-reactivity to non-tumor associated antigens of less than 15%; said antibody being radiolabeled with a pharmacologically inert radioisotope capable of detection with a photoscanning device, said labeling being effected to an extent sufficient to reduce the specific immunoreactivity of the antibody by from 5 to 33%; (b) indifferent immunoglobulin from the same or different species as that used to prepare said specific antibody, said indifferent immunoglobulin being radiolabeled with a pharmacologically inert radioisotope of a different element from that used to label the specific antibody and emitting at an energy capable of independent detection by said photoscanning device; and (c) a pharmaceutically acceptable injection vehicle.
Claim 12
Dependent Claim
137 words
An injectable composition, which comprises (a) a substantially monospecific antibody having a specific immunoreactivity of at least 70% to an intracellular marker substance produced by or associated with a tumor and a cross-reactivity to non-tumor associated antigens of less than 15%; said antibody being radiolabeled with a pharmacologically inert radioisotope capable of detection with a photoscanning device, said labeling being effected to an extent sufficient to reduce the specific immunoreactivity of the antibody by from 5 to 33%; (b) indifferent immunoglobulin from the same or different species as that used to prepare said specific antibody, said indifferent immunoglobulin being radiolabeled with a pharmacologically inert radioisotope of a different element from that used to label the specific antibody and emitting at an energy capable of independent detection by said photoscanning device; and (c) a pharmaceutically acceptable injection vehicle.
Claim 13
Dependent Claim
26 words
The composition of claim 9, wherein the specific antibody is specific to human chorionic gonadotropin (HCG) or its beta-subunit, alpha fetoprotein (AFP) or colon-specific antigen-p (CSAp).
Claim 14
Dependent Claim
33 words
The composition of claim 9, wherein the specific antibody is labeled with one of I-131, Ga-67, Tc-99m or In-111, and the indifferent immunoglobulin is labeled with another of I-131, Ga-67, Tc-99m or In-111.
Claim 15
Dependent Claim
25 words
The method of claim 1, wherein the radioisotopes used to label the specific antibody and the indifferent immunoglobulin both emit in the 10-5,000 kev range.
Claim 16
Dependent Claim
11 words
The method of claim 12, wherein said range is 100-500 kev.
Claim 17
Dependent Claim
25 words
The method of claim 7, wherein the radioisotopes used to label the specific antibody and the indifferent immunoglobulin both emit in the 10-5,000 kev range.
Claim 18
Dependent Claim
11 words
The method of claim 14, wherein said range is 100-500 kev.
Claim 19
Dependent Claim
25 words
The composition of claim 9, wherein the radioisotopes used to label the specific antibody and the indifferent immunoglobulin both emit in the 10-5,000 kev range.
Claim 20
Dependent Claim
11 words
The method of claim 16, wherein said range is 100-500 kev.
References Cited (Backward Citations)
US3960827A
Cited
US3927193A
Cited
US4160019A
Cited
US4144031A
Cited
US4174385A
Cited
US4146603A
Cited
EP0005638A2
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-07-17 | 1988-01-16 | 1988-07-17 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-07-17 | 1992-01-16 | 1992-07-17 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-07-17 | 1996-01-16 | 1996-07-17 | $7700.00 | Window Closed / Lapsed |